Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lentiviral Vector Gene Therapy in Sickle Cell Disease Using Autologous CD34+ Hematopoietic Stem Cells Collected Via Apheresis and Modified With a Lentiviral Vector

NCT06399107 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06399107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06399107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lentiviral Vector Gene Therapy in Sickle Cell Disease Using Autologous CD34+ Hematopoietic Stem Cells Collected Via Apheresis and Modified With a Lentiviral Vector
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2024
Completion date
December 28, 2025
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease, sickle-cell disease with crisis